Response rates in newly diagnosed multiple myeloma have improved dramatically with the introduction of highly effective novel therapies. However, survival in patients achieving optimal responses to initial treatment can vary significantly, and new prognostic indicators are required to improve risk stratification. We investigated the relationship between time to plateau (T Plat ) and survival in 1099 newly diagnosed patients treated with novel agents at our institution from 2005 to 2015. T Plat was defined as time from initiation of first-line therapy to best response to first-line therapy. The median T Plat was 4.9 months (0.7-58.6) and plateau duration was 1.8 years (0.2-11.0).
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Patients who required > 120 days to achieve a plateau had longer modified overall survival (mOS) and progression free survival (mPFS) calculated from a landmark of best response (P < .001 for both comparisons). Statistically significant improvement in mOS was retained in subgroup analysis based on age and whether patients received upfront autologous hematopoietic stem cell transplantation (ASCT) (P < .001 for all comparisons). Our results suggest that patients who respond more gradually to initial therapy (T Plat > 120 days) experience longer survival compared to more rapid responders. Patients with a prolonged T Plat could represent an "ongoing responder" phenotype that portends a survival advantage independent of treatment with upfront ASCT, depth of response, and biologic markers such as ISS stage and cytogenetic risk.
| I N TR ODU C TI ON
Multiple myeloma is an incurable plasma cell neoplasm that represents 1% of all cancers and 10% of hematologic malignancies in the United States. 1 Fortunately, the incorporation of novel agents into all lines of treatment, including immunomodulators (IMiD) and proteasome inhibitors (PI), has significantly improved response rates and survival for myeloma patients. [2] [3] [4] In the context of these new therapies, investigators have attempted to characterize the effect of prognostic factors such as depth and duration of best response on survival.
Several studies have shown that achieving a complete response (CR) with the use of novel agents significantly improves overall survival (OS). [5] [6] [7] In addition, the percentage of patients achieving a CR has increased significantly with the advent of improved therapies. . 18 OS was defined as the time from diagnosis to death. PFS was defined from the time of diagnosis to disease relapse or death. To avoid an immortal time bias, modified overall (mOS) and progression free survival (mPFS) estimates were calculated from the time of best response to first-line therapy (landmark analysis). 19 Patients were censored at the end of follow-up if no event had occurred. mOS and mPFS estimates were calculated using the method described by Kaplan and Meier. 20 The log-rank test was used to compare survival outcomes in subgroups. Unadjusted and multivariableadjusted proportional hazards regression models were fit to assess the association between T Plat and survival outcomes.
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The multivariable-adjusted models included the following baseline characteristics: Model 1 was adjusted for age, sex, and best response to first-line therapy. Model 2 was additionally adjusted for the type of first-line therapy (IMiD, PI, upfront ASCT). 
| Baseline demographic and clinical features
Demographics and clinical data are outlined in 
| Survival analysis
In the survival analysis, T Plat was dichotomized into two groups, those requiring 120 days and > 120 days to achieve the best response. As illustrated in Figure 1 , patients who required > 120 days to achieve a plateau had longer mOS and mPFS calculated from a landmark of best response (P < .001 for both comparisons). With respect to type of therapy, neither IMiD (HR 0.75, 95% CI 0.53-1.06, P 5 .098) nor PI (HR 0.91, 95% CI 0.65-1.26, P 5 0.577) were associated with mOS after adjusting for age, sex, best response during first-line therapy, upfront ASCT, and T Plat . Supporting Information Figure S1 demonstrates similar results when survival estimates were performed from diagnosis. A separate analysis was performed for T Plat 240 and > 240 days. Again, patients requiring > 240 days to achieve a plateau demonstrated longer survival both from a landmark of best response (Supporting Information Figure S2 ) and diagnosis (Supporting Information Figure S3 ) (P < .001
for all comparisons).
Survival analysis was also performed for subgroups including age < 65 and 65 years-old, and whether patients received upfront
ASCT. As demonstrated in Figure 2 , statistically significant improvement in mOS is retained for patients requiring > 120 days to achieve plateau in each subgroup (P < .001 for all comparisons). For the subgroup undergoing upfront ASCT, the duration of induction in months (time from initiation of chemotherapy to transplantation) was not associated with mOS (HR 0.97, 95% CI 0.92-1.03, P 5 .288). In addition, maintenance therapy after upfront ASCT was not associated with mOS (HR 0.73, 95% CI 0.44-1.20, P 5 .213).
Four multivariable adjusted cox regression models were developed for the entire cohort to adjust for differences in other prognostic factors between groups requiring 120 days and > 120 days to achieve a best response (Table 2) . Differences in mOS and mPFS between the two groups remained statistically significant for all four adjusted models. As demonstrated in Supporting Information Table S2 , this was also true for OS and PFS (nonlandmark) estimates taken from initial diagnosis.
There was no statistically significant interaction between upfront ASCT and T Plat in the multivariable-adjusted models (P 5 .192 
| D ISC USSION
We investigated the association between T Plat and survival outcomes in patients with newly diagnosed multiple myeloma because few studies have addressed this relationship in the era of novel agents. The multivariable-adjusted models included the following baseline characteristics: Model 1 was adjusted for age, sex, and best response during first-line therapy. Model 2 was additionally adjusted for the type of first-line therapy (immunomodulator, proteasome inhibitor, upfront autologous hematopoietic stem cell transplantation). Model 3 was additionally adjusted for the paraprotein concentration (M spike). Model 4 was additionally adjusted for the International Staging System (ISS) stage and the presence of cytogenetic high-risk abnormalities.
and diagnosis. Ultimately, employing a landmark analysis overcomes "time to response bias," or the concept that ongoing responders cannot meet the endpoint of progression or death and therefore demonstrate improved PFS and OS compared to nonresponders. 23 The effect of T Plat on survival for the entire cohort was independent of potential confounders including age, sex, depth of response, treatment modality, initial M spike, ISS stage and high-risk cytogenetics.
In contrast, neither IMiD nor PI were associated with improved survival when controlling for known prognostic factors. We acknowledge that ASCT is a powerful treatment modality and represents the standard of care for eligible patients. Thus, special attention was given to the effect of transplantation on the association between T Plat and survival. The effect of T Plat on mOS and mPFs was maintained in separate regression modeling based on transplantation status. Moreover, survival analyses demonstrated improved mOS for patients with T Plat > 120 days in both upfront ASCT and nonupfront ASCT groups. In patients undergoing upfront ASCT, the duration of induction and incorporation of maintenance therapy had no significant effect on overall survival. These results suggest that our conclusions can be applied to patients treated with or without upfront ASCT.
In interpreting these results, it is possible that multiple myeloma responding more gradually to initial treatment portends some biologic advantage that is independent of, and not simply a surrogate for, cytogenetic risk and ISS stage. These patients may represent an "ongoing responder" phenotype that is less prone to developing treatment resistance and subsequent disease progression. In contrast, rapid responders may be more predisposed to subsequent treatment resistance, relapse, and death. This pattern has been codified in observations of other malignances such as small cell carcinoma and Burkitt lymphoma, where marked initial sensitivity to chemotherapy is maligned by early resistance and relapse. 24, 25 Lastly, our results suggest that patients who fail to achieve an early, deep clinical response should continue to receive aggressive therapy, with the goal of achieving stepwise improvement, and thus ongoing response to treatment.
Several studies performed in nontransplant populations prior to the introduction of novel agents reached similar conclusions with respect to survival in fast versus slow responders to therapy. 26, 27 In contrast, other authors report improved survival in rapid responders. 28 However, in all of the aforementioned studies, response was categorized based on percent reduction in serum M protein alone. Unlike our analysis, none of these studies classify response in terms of presentday IMWG criteria, and therapies did not include novel agents.
This study is one of few in the era of novel therapies for multiple myeloma to address the association between the kinetics of treatment response and survival in newly diagnosed disease. Previous studies exploring this relationship have produced conflicting results. For example, one study demonstrated that rapid reductions in serum M protein in response to bortezomib based regimens were associated with longer time to progression in the relapsed-refractory, non-ASCT setting. 15 In contrast, in a clinical trial employing novel agents for nontransplant eligible myeloma, there was no difference in OS, PFS or duration of CR between patients achieving a CR before and after 6 months of therapy. 6 Lastly, a prospective study of newly diagnosed patients treated with upfront ASCT found that those with the most rapid reductions in serum free light chains following induction had the worst OS. 16 Our findings expand on these results by demonstrating a survival benefit to more gradual clinical response in newly diagnosed multiple myeloma treat with novel agents, in both upfront ASCT and nonupfront ASCT populations.
We adjusted for several known prognostic factors including patient characteristics, treatment modalities, and disease severity based on established literature. The effect of T Plat on survival outcomes remained consistent when adjusting for these factors, suggesting an independent prognostic value. The strengths of this study include the use of a large, representative patient population with few exclusion criteria and several years of follow-up.
